NeOnc Technologies
Westlake Village, California, United States · Biotechnology, Healthcare, Health Care
NeOnc is the developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB). Using NeOnc’s formulations, pharma companies that have limited success with their CNS therapeutics because of current delivery restrictions may be able to provid
Key facts
- Headquarters
- Westlake Village, California, United States
- Employees
- 7
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (NTHI)
- Website
- neonctech.com
- Company page
Recent activity at NeOnc Technologies
- : SEC 8-K (7.01): On November 2, 2026, NeOnc Technologies Holdings, Inc. issued a press release regarding the presentation of data from its intranasal NEO100 and oral NEO212 programs. The results will be showcased in two posters at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology, scheduled to take place from November 12 to November 15, 2026, in Philadelphia, Pennsylvania. This disclosure is significant as it highlights the company's ongoing research efforts in the neuro-oncology space, which could potentially impact investor sentiments and market position. The filing is pursuant to Regulation FD, ensuring transparency with shareholders and the market.
- : NeOnc Technologies Signs MoU with Abu Dhabi Department of Health
- : SEC 8-K (7.01):
- : SEC 8-K (5.02):
- : SEC 8-K (7.01): On September 28, 2026, NeOnc Technologies Holdings, Inc. announced via a press release that it is scheduled to meet with the U.S. Food and Drug Administration on November 17, 2026. This meeting is an End-of-Phase 1 Type B meeting concerning their product NEO212, which is significant as it marks a critical regulatory step in the drug's development process. The anticipated discussions will likely address the next steps for regulatory approval. The press release is included as Exhibit 99.1 in the filing. This meeting represents an important milestone for the company and could impact its future strategic direction.
- : SEC 8-K (7.01):
- : SEC 8-K (7.01): On September 16, 2026, NeOnc Technologies Holdings, Inc. disclosed that Amir F. Heshmatpour, the Executive Chairman, President, and CEO of the company, purchased an additional 35,000 shares of common stock in the open market for approximately $115,400, which amounts to a weighted average price of approximately $3.30 per share. The transaction took place on September 15, 2026, showcasing the CEO's confidence in the company's future potential. This disclosure was provided in a press release, which is attached as Exhibit 99.1 to the filing, and emphasizes the management's commitment to aligning their interests with those of the shareholders.
- : SEC 8-K (1.01): On September 8, 2026, NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement with certain institutional investors for a registered direct offering. The agreement involves the sale of an aggregate of 2,610,715 shares of the Company's common stock at an offering price of $4.20 per share, along with pre-funded warrants to purchase 960,715 shares and accompanying warrants to purchase up to 3,571,430 shares. The strategic implication of this agreement is to raise capital through equity financing, potentially to fund operations or other business initiatives. The agreement highlights the Company's ongoing efforts to support its financial position and growth strategy.
- : SEC 8-K (7.01): On August 12, 2026, NeOnc Technologies Holdings, Inc. hosted an investor conference call to discuss the results from the Phase 2a portion of their clinical study NEO100-01. This call is significant as it provides insight into the company's progress and potentially impacts investor sentiment and market perception. The transcript of the call has been furnished as Exhibit 99.1, which details the findings and strategic direction of the therapy being reviewed. The filing is intended for disclosure purposes and is not deemed 'filed' under the Securities Exchange Act, hence it does not carry usual filing liabilities.
- : SEC 8-K (7.01): On August 12, 2026, NeOnc Technologies Holdings, Inc. issued a press release and hosted an investor conference call to announce results from the Phase 2a portion of NEO100-01. This filing includes a press release as Exhibit 99.1 and an investor presentation as Exhibit 99.2. The Company provided updates that are significant for investors, focusing on the implications of the trial results for future developments. Given the timeliness of this disclosure, it aims to inform security holders about recent advancements in their clinical trials.
NeOnc Technologies funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Venture | $15.0M |
| Feb 2026 | Venture | $10.6M |
| Dec 2025 | Venture | $1.0M |
| Apr 2025 | Seed | $1.6M |
| Mar 2025 | Venture | $10.0M |
Leadership
- Thomas Chen, CEO, CSO, Founder, NeOnc Technologies Inc.
- Patrick Walters, Executive Officer, Director
- Jim Walters, Executive Officer, Director
- Vicki Shih, Director
- Matthew Lin, Director
- Clovis Fonseca, Director
- Alan Chiang, Director
Verified email and direct lines for NeOnc Technologies’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
NeOnc Technologies in the news
- NeOnc Technologies Holdings, Inc. (NTHI) Stock Price, News, Quote & History - Yahoo! Finance Canada (Oct 31, 2026)
- NeOnc Technologies Holdings Announces Effectiveness of Registration Statement and Anticipated Listing Date of Common Stock on Nasdaq Global Market - Yahoo Finance (Mar 25, 2025)
- NeOnc Technologies Holdings, Inc. (NTHI) stock price, news, quote and history - Yahoo Finance UK (Jun 30, 2025)
- NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy - Yahoo Finance (Apr 08, 2025)
Companies similar to NeOnc Technologies
- Optimize Systems · Biotechnology, Healthcare, Health Care, Information Technology, Medical
- pulseData, Inc. · Biotechnology, Healthcare, Health Care, Information Technology, Medical
- Dror Ortho-Design · Biotechnology, Healthcare, Health Care, Information Technology, Medical
- Phreesia · Biotechnology, Healthcare, Health Care, Information Technology, Medical
- Siloton · Biotechnology, Health Care, Information Technology, Medical
About NeOnc Technologies: questions and answers
What does NeOnc Technologies do?
NeOnc is the developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB). Using NeOnc’s formulations, pharma companies that have limited success with their CNS therapeutics because of current delivery restrictions may be able to provid
Where is NeOnc Technologies headquartered?
NeOnc Technologies is headquartered in Westlake Village, California, United States.
How many employees does NeOnc Technologies have?
NeOnc Technologies has about 7 employees.
Has NeOnc Technologies raised funding?
Yes. Fundz has recorded 5 funding events for NeOnc Technologies. The most recent, $15.0M, was in Jun 2026.
Who leads NeOnc Technologies?
Thomas Chen is a CEO, CSO, Founder, NeOnc Technologies Inc. at NeOnc Technologies.
What is the latest news on NeOnc Technologies?
On Nov 03, 2026, SEC 8-K (7.01): On November 2, 2026, NeOnc Technologies Holdings, Inc. issued a press release regarding the presentation of data from its intranasal NEO100 and oral NEO212 programs. The results will be showcased in two posters at the 31st Annual Meeting and Education Day of the Society for Neuro-Onc
Is NeOnc Technologies a public company?
Yes. NeOnc Technologies is publicly traded under the ticker NTHI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy